Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 312 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hypothalamic-pituitary Disorders Clear all
Completed Phase 3 Interventional Results available

Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel

NCT00447499
View directory record Official record
Conditions
Acromegaly
Interventions
Somatuline Autogel (lanreotide acetate), Home administration
Drug · Behavioral
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
13
States / cities
La Mesa, California • Los Angeles, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Phase 1 Interventional

Acupuncture to Reduce Symptoms of Advanced Colorectal Cancer

NCT00034034
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Acupuncture
Procedure
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2007 · Synced Oct 21, 2026, 9:41 AM EDT
Recruiting No phase listed Observational

A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA

NCT05820672
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
No intervention
Other
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
Not listed
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
27
States / cities
Phoenix, Arizona • Orange, California • Sacramento, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Phase 2 Interventional

SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

NCT05307328
View directory record Official record
Conditions
Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion, Cortisol Excess, Cortisol; Hypersecretion, Cortisol Overproduction, Ectopic ACTH Secretion
Interventions
SPI-62, Placebo
Drug
Lead sponsor
Sparrow Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
8
States / cities
Phoenix, Arizona • Fort Myers, Florida • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Phase 2Phase 3 Interventional

Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly

NCT00234572
View directory record Official record
Conditions
Acromegaly
Interventions
Lanreotide (Autogel formulation)
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2019 · Synced Oct 21, 2026, 9:41 AM EDT
Terminated Phase 3 Interventional

Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD)

NCT02410356
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
TV-1106, dGH
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
32
States / cities
Artesia, California • Fountain Valley, California • Lakewood, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Provocative Testing Using LHRH and hCG of the Pituitary-Gonadal Axis in Persons With Spinal Cord Injury.

NCT00223860
View directory record Official record
Conditions
Hypogonadism, Spinal Cord Injury
Interventions
Human chorionic gonadotropin (hCG), Luteinizing hormone releasing hormone (LHRH)
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 65 Years · Male only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2007
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2008 · Synced Oct 21, 2026, 9:41 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate MAR002 for Acromegaly

NCT07641179
View directory record Official record
Conditions
Acromegaly
Interventions
MAR002, Placebo
Drug
Lead sponsor
Marea Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Phoenix, Arizona • Columbus, Ohio • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Phase 2 Interventional Results available

Inhaled Oxytocin and HPA Axis Reactivity

NCT03593473
View directory record Official record
Conditions
Depression, Postpartum, Anxiety Disorders, Stress, Psychological
Interventions
Intranasal Oxytocin, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors

NCT01689727
View directory record Official record
Conditions
Pituitary Tumors
Interventions
Technetium Tc 99m EC20
Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 21, 2026, 9:41 AM EDT
Terminated Phase 3 Interventional Results available

Treatment of Psychotic Major Depression With Mifepristone

NCT00867360
View directory record Official record
Conditions
Affective Disorders, Psychotic, Depressive Disorder
Interventions
Mifepristone (RU-486), Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
21 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Phase 3 Interventional Results available

Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma

NCT02483975
View directory record Official record
Conditions
Asthma
Interventions
FF, Placebo, Montelukast, Albuterol/Salbutamol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 11 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Little Rock, Arkansas • Alhambra, California • Costa Mesa, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Oct 21, 2026, 9:41 AM EDT
Recruiting No phase listed Observational

Evaluation and Treatment of Neurosurgical Disorders

NCT00060541
View directory record Official record
Conditions
Neurologic Disorders
Interventions
Laboratory tests, Radiological exams
Procedure
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
4 Years to 99 Years
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Cortisol Resistance in Young Sedentary and Endurance-Trained Men

NCT01294319
View directory record Official record
Conditions
Cortisol Resistance, Negative Feedback, ACTH, Mineralcorticoid, Glucocorticoid
Interventions
Mifepristone, Placebo, Spironolactone, Combined, Dexamethasone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 80 Years · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis

NCT01378429
View directory record Official record
Conditions
Perennial Allergic Rhinitis, PAR
Interventions
ciclesonide nasal aerosol, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
7
States / cities
Costa Mesa, California • Stockbridge, Georgia • Normal, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Oct 21, 2026, 9:41 AM EDT
Recruiting No phase listed Observational

Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)

NCT04543253
View directory record Official record
Conditions
Cushing Syndrome
Interventions
MUSE biofeedback
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 21, 2026, 9:41 AM EDT
Completed No phase listed Observational

Stress, Hypothalamic-pituitary-adrenal (HPA) Dysfunction, and Relapse in Alcoholism

NCT00744588
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome

NCT00569582
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
17
States / cities
Birmingham, Alabama • Escondido, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Oct 21, 2026, 9:41 AM EDT
Recruiting No phase listed Observational

Observation of Environment and Reproductive-Endocrine Effects

NCT06280807
View directory record Official record
Conditions
Hypogonadism, Hypergonadism, Precocious Puberty, Late Puberty, Amenorrhea
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
8 Years to 99 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2039
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly

NCT01412424
View directory record Official record
Conditions
Acromegaly
Interventions
Octreotide capsules
Drug
Lead sponsor
Chiasma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 21, 2026, 9:41 AM EDT
Not listed Phase 2 Interventional

Growth Hormone Replacement Therapy for Retried Professional Football Players

NCT04121780
View directory record Official record
Conditions
TBI (Traumatic Brain Injury), Concussion, Brain, Sport Injury, Anterior Pituitary Hyposecretion Syndrome, Hypopituitarism, Growth Hormone Deficiency
Interventions
Growth Hormone, Placebo
Biological · Other
Lead sponsor
Center for Neurological Studies
Other
Eligibility
18 Years to 76 Years · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Dearborn, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 21, 2026, 9:41 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Feasibility of Breathwork Intervention With Older Adults After Knee Surgery

NCT07464860
View directory record Official record
Conditions
Surgical Stress Response, Stress Physiological, Stress Physiology, Stress Psychological, Breathing Techniques, Breathing Exercises, Hypothalamic Pituitary Adrenal, Relaxation, Relaxation Therapy, Cortisol, Postoperative Pain, Postoperative Anxiety, Postoperative Depression, Quality of Recovery (QoR-15)
Interventions
A 5-minute Asynchronous Breathwork Intervention, A 5-minute Asynchronous Card Game Video
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
65 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Phase 2 Interventional

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

NCT05199584
View directory record Official record
Conditions
Solid Tumors With PTCH1 Loss-of-function Mutations
Interventions
ENV-101 (taladegib)
Drug
Lead sponsor
Endeavor Biomedicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
16
States / cities
Los Angeles, California • Santa Rosa, California • Tampa, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease

NCT02697734
View directory record Official record
Conditions
Cushing's Disease
Interventions
osilodrostat, osilodrostat Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
6
States / cities
Aurora, Colorado • Ann Arbor, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 21, 2026, 9:41 AM EDT